ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, that is in a clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in a clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm.